Guardant Health, Inc. beat EPS estimates 50% of the time across 16 reported quarters (8 beats, 8 misses), averaging -9.8% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.74 | $-0.89 | -20.3% | Miss | Q2 FY26 call |
| Q1 FY26 | $-0.71 | $-0.85 | -19.7% | Miss | Q1 FY26 call |
| Q3 FY25 | $-0.80 | $-0.74 | +7.5% | Beat | |
| Q2 FY25 | $-0.79 | $-0.79 | +0.0% | Beat | |
| Q1 FY25 | $-0.78 | $-0.77 | +1.3% | Beat | |
| Q4 FY24 | $-0.74 | $-0.90 | -21.6% | Miss | |
| Q3 FY24 | $-0.79 | $-0.88 | -11.4% | Miss | |
| Q2 FY24 | $-0.82 | $-0.71 | +13.4% | Beat | |
| Q1 FY24 | $-0.94 | $-0.94 | +0.0% | Beat | |
| Q4 FY23 | $-0.93 | $-1.58 | -69.9% | Miss | |
| Q3 FY23 | $-0.93 | $-0.73 | +21.5% | Beat | |
| Q2 FY23 | $-1.25 | $-0.67 | +46.4% | Beat |
Back to GH overview · GH holders · GH KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.